Booming Jobs Report, Plummeting Market: What's Going On? | ITK With Cathie Wood

TLT is the iShares 20+ Year Treasury Bond ETF, providing exposure to U.S.

Most direct expression of falling long-end yields; aligns with the transcript’s long-bond focus.

Moderate-duration alternative if long-end volatility is high.

The composition and weighting of the securities portion of a portfolio deposit are also adjusted to conform to changes in the index.

Often benefits from declining yields/disinflation and a lower discount rate.

ARKK is an actively managed exchange-traded fund seeking long-term growth by investing in companies expected to benefit from disruptive innovation.

High duration/innovation tilt; tends to be very rate-sensitive.

SpaceX IPO, Anthropic Fable 5, And Roku | The Brainstorm EP 136

In this episode of FYI, Brett Winton and Chase Prather host Andy Tang, partner at Draper Associates, to discuss how venture capital is evolving alongside AI, deep tech, and shifting market dynamics. Andy reflects on his 20-year investing career, the growing importance of AI-native companies, and why the cost of execution is rapidly declining for startups. The conversation explores founder psychology, the role of contrarian investing, and how Draper approaches unconventional ideas ranging from artificial wombs to AI-generated companies and personalized cancer therapies. Andy also shares insights on venture ecosystems, market cycles, and the characteristics that separate enduring founders from everyone else. Key Points From This Episode: 00:00:00 Introduction 00:06:09 How AI-native startups are reshaping venture capital strategies. 00:20:47 Why the cost of building companies is falling dramatically. 00:28:18 How venture ecosystems evolve through successful Initial Public Offering (IPO) cycles. 00:42:11 How venture investors evaluate founder ambition and long-term outcomes. 00:50:02 How AI could enable single-person or founderless companies. 00:53:26 The idea of growing replacement or

Discussion touches on Apple WWDC/Siri AI positioning (long-term AI strategy), AI model/cloud partnerships that may be short-term (Anthropic/Google), and large-scale data center buildouts (xAI/SpaceX mentioned but private). Actionable public-market read-through is mainly: AAPL (on-device AI/WWDC), major cloud platforms (GOOGL, MSFT, AMZN), and AI data-center supply chain (NVDA).

ARK Big Ideas 2026 segment on tokenized assets references U.S. regulatory momentum ("GENIUS Act" in June 2025) and cites JPMorgan announcements around tokenized stocks on its platform. Content is high-level and lacks concrete details (no specific products, timelines, volumes, or economics), limiting near-term trade actionability.

Video-style commentary featuring Cathie Wood riding in a Tesla Robotaxi in Austin and arguing the Robotaxi rollout is shifting from slow progress to rapid adoption (“slowly…then all at once”), emphasizing safety vs human driving and long-term (10-year) disruption. The content is thematic and promotional; it provides limited hard catalysts/dates but supports a medium/long-horizon autonomy thesis centered on Tesla.

Transcript-style macro discussion (Cathie Wood context) touching on: strong jobs report vs weak market, USD (DXY) dynamics, foreign selling of US Treasuries, gold selling by some countries, M2 leading indicators pointing to disinflation/deflation, long-bond yield implications, OPEC “splintering”/UAE production, PPI/core PPI cooling, decelerating corporate revenue growth (margin implications), and housing buyer/seller imbalance. Content is thematic but low on concrete timing/levels.

The source is a fragmented discussion about large private-company revenue/ARR milestones (e.g., “$30B ARR”), comparisons to early NASDAQ-era growth, and a broad “historic IPO wave” framing, with mentions of SpaceX, xAI/Grok, Anthropic, and OpenAI. It contains no concrete timing, pricing, filing details, or specific IPO candidates beyond speculative references, so actionable trading signal is limited.

Podcast-style discussion with Bryan Johnson framed around “don’t die”/longevity: prioritizing interventions that extend healthspan, skepticism toward many supplements (NMN/NR, B12 shots), importance of sleep architecture, and a view that AGI/ASI could become a major driver of longevity progress. No company-specific catalysts, products, trials, or investable signals are provided; ARK disclaimers included.